Treatment with radiolabeled somatostatin analogs is a promising new tool in the management of patients who have inoperable or metastasized endocrine tumors. Symptomatic improvement may occur with all111In-,90Y-, or177Lu-labeled somatostatin analogs that have been used for peptide receptor radionuclide therapy. The results that were obtained with [90Y-DOTA°,Tyr3]octreotide and [177Lu-DOTA°,Tyr3]octreotate are encouraging in tumor regression. Also, if kidney-protective agents are used, the side effects of this therapy are few and mild. These data compare favorably with the limited number of alternative treatment approaches.,
Hematology / Oncology Clinics of North America
Erasmus MC: University Medical Center Rotterdam

Kwekkeboom, D., Teunissen, J., Kam, B., Valkema, R., de Herder, W., & Krenning, E. (2007). Treatment of Patients Who Have Endocrine Gastroenteropancreatic Tumors with Radiolabeled Somatostatin Analogues. Hematology / Oncology Clinics of North America (Vol. 21, pp. 561–573). doi:10.1016/j.hoc.2007.04.009